In terms of expenditure on treatments, Greece physician respondents reported a higher percentage of CKD patients requiring haemodialysis (HD) (15%) and utilisation of erythropoietin stimulating agents (ESA) (15%) compared to the other three countries where utilisation rates were under 5%. This evidence concerns the gene EPO and chronic kidney disease.